Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HYDRO-SERP "50" vs ALDORIL D50
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hydrochlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water. Reserpine depletes catecholamines (norepinephrine, dopamine) from peripheral sympathetic nerve endings, reducing vascular tone and heart rate.
Aldoril D50 is a combination of methyldopa and hydrochlorothiazide. Methyldopa is a centrally-acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume and further lowering blood pressure.
Hypertension
Hypertension (first-line or second-line therapy),Hypertensive urgency (off-label)
Hydrochlorothiazide 50 mg orally once daily.
1 tablet (hydrochlorothiazide 25 mg + methyldopa 250 mg) orally twice daily; maximum dose: 2 tablets (50 mg + 500 mg) twice daily.
50-100 hours (prolonged in renal impairment; half-life up to 200 hours in severe renal disease)
3–6 hours (terminal elimination half-life); clinical context: requires twice-daily dosing for sustained blood pressure control; prolonged in renal impairment.
Hydrochlorothiazide is not extensively metabolized. Reserpine is metabolized primarily in the liver by CYP450 enzymes.
Methyldopa is extensively metabolized in the liver via conjugation and O-methylation, with involvement of catechol-O-methyltransferase (COMT). Hydrochlorothiazide is not extensively metabolized; it is eliminated largely unchanged by the kidneys.
Renal (50-70% as unchanged drug and metabolites), biliary/fecal (20-30%)
Renal: 50% as unchanged drug and 20% as metabolites; biliary/fecal: ~25% (as metabolites); total renal clearance accounts for ~70% of elimination.
90-96% (primarily to albumin and alpha1-acid glycoprotein)
~20% bound to albumin; minimal binding to other plasma proteins.
200-400 L/kg (extremely large due to extensive tissue binding, especially in adrenergic nerve terminals)
0.2–0.3 L/kg (moderately low Vd, indicating limited extravascular distribution and predominantly plasma water distribution).
Oral: 40-50% (extensive first-pass metabolism)
Oral: 30–40% (due to extensive first-pass metabolism); IV: 100%.
Contraindicated in anuria. For GFR 30-60 m L/min: reduce dose to 25 mg daily. For GFR <30 m L/min: not recommended.
Contraindicated if GFR < 30 m L/min; for GFR 30-50 m L/min: reduce dose and monitor electrolytes.
Child-Pugh A: no adjustment. Child-Pugh B/C: use with caution; monitor electrolytes and renal function; reduce dose if needed.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50% and monitor; Class C: contraindicated.
Not typically recommended; safety and efficacy not established.
Not recommended; inadequate safety data.
Initiate at 12.5-25 mg orally once daily; titrate cautiously; monitor electrolytes and renal function.
Start with 1 tablet (hydrochlorothiazide 12.5 mg + methyldopa 125 mg) once daily; increase slowly; monitor for hypotension and electrolyte imbalance.
None
None
Electrolyte imbalance (especially hypokalemia),Sulfonamide allergy (hydrochlorothiazide),Mental depression (reserpine),Bradycardia and arrhythmias (reserpine)
Sedation and drowsiness common; avoid driving or hazardous activities. Risk of Coombs-positive hemolytic anemia with methyldopa (discontinue if anemia develops). Hepatotoxicity and liver function abnormalities (discontinue if jaundice occurs). Orthostatic hypotension; caution in volume-depleted patients. Electrolyte imbalances (particularly hypokalemia, hyponatremia) with hydrochlorothiazide; monitor serum electrolytes. Sulfonamide cross-sensitivity possible. Exacerbation of systemic lupus erythematosus. Avoid abrupt withdrawal of methyldopa (may cause rebound hypertension).
Anuria,Known sulfonamide allergy (hydrochlorothiazide),History of mental depression (reserpine),Active peptic ulcer or ulcerative colitis (reserpine),Electroconvulsive therapy (reserpine)
Active hepatic disease (cirrhosis, hepatitis) associated with methyldopa therapy; previous methyldopa-induced liver disorders. Anuria or hypersensitivity to thiazide diuretics or sulfonamide-derived drugs. Concomitant use with MAO inhibitors. Severe renal impairment (creatinine clearance <30 m L/min) or electrolyte depletion due to hydrochlorothiazide. Concurrent lithium therapy (risk of lithium toxicity).
Avoid high-sodium foods (e.g., processed meats, canned soups) to prevent fluid retention and counteract antihypertensive effects. Avoid excessive potassium-rich foods (e.g., bananas, oranges, spinach) as thiazides cause potassium loss; however, reserpine may not affect potassium levels. Limit alcohol intake. Take with food or milk to reduce gastrointestinal upset.
Avoid potassium supplements or salt substitutes containing potassium without consulting doctor. Limit alcohol intake. Avoid excessive grapefruit juice. Maintain adequate potassium intake through diet to prevent hypokalemia.
Hydrochlorothiazide: First trimester: Crosses placenta, risk of fetal or neonatal jaundice, thrombocytopenia, and possibly other adverse effects; limited human data, association with congenital anomalies not established. Second and third trimesters: May cause fetal or neonatal electrolyte disturbances, hypoglycemia, and decreased placental perfusion. Reserpine: First trimester: Animal studies show no teratogenic effects, human data insufficient. Second and third trimesters: May cause neonatal respiratory depression, bradycardia, hypothermia, and nasal congestion due to depletion of catecholamines.
Hydrochlorothiazide (HCTZ) is Pregnancy Category B in first trimester and Category D in second/third trimesters. Methyldopa (M) is Category B. HCTZ use in second/third trimester may cause fetal/neonatal effects including electrolyte disturbances, jaundice, thrombocytopenia, and possible fetal growth restriction. Methyldopa has not shown teratogenicity. Aldoril D50 (M 500mg/HCTZ 50mg) is not recommended during pregnancy, especially after first trimester.
Hydrochlorothiazide: Excreted into human milk in small amounts; M/P ratio approximately 0.2. Reserpine: Excreted into breast milk; M/P ratio not well established. Both are considered compatible with breastfeeding by most authorities, but use caution as reserpine may cause gastrointestinal disturbances, nasal congestion, and lethargy in the infant. Monitor infant for side effects.
Both methyldopa and HCTZ are excreted in breast milk. Methyldopa M/P ratio approximately 1.0; HCTZ M/P ratio variable, small amounts. Use during breastfeeding may suppress lactation due to HCTZ diuretic effect. Monitor infant for signs of hypotension, electrolyte imbalance. Caution recommended; use only if clearly needed.
Hydrochlorothiazide: Dose adjustment not typically required for pharmacokinetic changes, but use lowest effective dose due to risk of decreased placental perfusion. Reserpine: No specific dose adjustment recommended for pregnancy. Monitor for hypotension and avoid use near term to reduce neonatal adverse effects.
Pregnancy-induced increase in plasma volume may reduce effectiveness of HCTZ, requiring dose adjustment. Methyldopa pharmacokinetics not significantly altered; however, increased clearance in pregnancy may require higher doses. In preeclampsia, dose adjustments may be needed. Avoid HCTZ in pregnancy if possible.
Hydrochlorothiazide 50 mg plus reserpine 0.125 mg. Monitor serum potassium and magnesium; hypokalemia increases digitalis toxicity risk. Reserpine may cause depression; avoid in patients with history of depression. Onset of antihypertensive effect is 3-6 hours. Use with caution in patients with renal impairment (Cr Cl <30 m L/min) as thiazides are ineffective.
ALDORIL D50 combines methyldopa and hydrochlorothiazide. Monitor for orthostatic hypotension, especially in volume-depleted patients. May cause positive Coombs test, hemolytic anemia, and lupus-like syndrome. Avoid in pheochromocytoma. Use caution in hepatic disease.
Take this medication exactly as prescribed, usually once daily in the morning to avoid nighttime urination.,This drug may make you dizzy; avoid driving or operating machinery until you know how it affects you.,Reserpine can cause nasal congestion, drowsiness, or depression; contact your doctor if you experience mood changes.,Avoid alcohol as it may increase dizziness and drowsiness.,Stay hydrated but do not overhydrate; report excessive thirst, dry mouth, or muscle cramps.,Do not stop taking this medication abruptly as it may cause a rapid increase in blood pressure.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double the dose.,This medication may increase your sensitivity to sunlight; use sunscreen and protective clothing.
Take exactly as prescribed; do not skip doses or double up.,May cause dizziness or drowsiness; avoid driving until you know how it affects you.,Report unexplained fever, jaundice, or dark urine immediately.,Avoid sudden discontinuation; may cause rapid increase in blood pressure.,Stay hydrated but do not overhydrate; monitor for signs of electrolyte imbalance.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HYDRO-SERP "50" vs ALDORIL D50, answered by our medical review team.
HYDRO-SERP "50" is a Antihypertensive Combination that works by Hydrochlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water. Reserpine depletes catecholamines (norepinephrine, dopamine) from peripheral sympathetic nerve endings, reducing vascular tone and heart rate.. ALDORIL D50 is a Antihypertensive Combination that works by Aldoril D50 is a combination of methyldopa and hydrochlorothiazide. Methyldopa is a centrally-acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume and further lowering blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HYDRO-SERP "50" and ALDORIL D50 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HYDRO-SERP "50" is: Hydrochlorothiazide 50 mg orally once daily.. The standard adult dose of ALDORIL D50 is: 1 tablet (hydrochlorothiazide 25 mg + methyldopa 250 mg) orally twice daily; maximum dose: 2 tablets (50 mg + 500 mg) twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HYDRO-SERP "50" and ALDORIL D50 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HYDRO-SERP "50" is classified as Category C. Hydrochlorothiazide: First trimester: Crosses placenta, risk of fetal or neonatal jaundice, thrombocytopenia, and possibly other adverse effects; limited human data, association wi. ALDORIL D50 is classified as Category C. Hydrochlorothiazide (HCTZ) is Pregnancy Category B in first trimester and Category D in second/third trimesters. Methyldopa (M) is Category B. HCTZ use in second/third trimester ma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.